{"id":"https://openalex.org/W7126246972","doi":"https://doi.org/10.2337/figshare.30916430","title":"Gout-Related Medication Use After Initiating Sodium Glucose Co-Transporter-2 Inhibitors in Patients with Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.","display_name":"Gout-Related Medication Use After Initiating Sodium Glucose Co-Transporter-2 Inhibitors in Patients with Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.","publication_year":2026,"publication_date":"2026-01-30","ids":{"openalex":"https://openalex.org/W7126246972","doi":"https://doi.org/10.2337/figshare.30916430"},"language":"en","primary_location":{"id":"doi:10.2337/figshare.30916430","doi":"https://doi.org/10.2337/figshare.30916430","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.30916430","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.2337/figshare.30916430","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058955589","display_name":"Chio Yokose","orcid":"https://orcid.org/0000-0001-7557-3303","observed_orcids":["https://orcid.org/0000-0001-7557-3303"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chio Yokose","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083145701","display_name":"Na Lu","orcid":"https://orcid.org/0000-0003-1075-5573","observed_orcids":["https://orcid.org/0000-0003-1075-5573"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Na Lu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076997901","display_name":"Deborah J. Wexler","orcid":"https://orcid.org/0000-0001-6979-402X","observed_orcids":["https://orcid.org/0000-0001-6979-402X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Deborah J. Wexler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000396081","display_name":"Sharan K. Rai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sharan K. Rai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029053241","display_name":"Gregory J. Challener","orcid":"https://orcid.org/0000-0002-2844-4661","observed_orcids":["https://orcid.org/0000-0002-2844-4661"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory J. Challener","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5124426365","display_name":"J. Antonio Avi\u00f1a-Zubieta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Antonio Avi\u00f1a-Zubieta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001881870","display_name":"Rozalina G. McCoy","orcid":"https://orcid.org/0000-0002-2289-3183","observed_orcids":["https://orcid.org/0000-0002-2289-3183"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rozalina G. McCoy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029895122","display_name":"Ran Abuhasira","orcid":"https://orcid.org/0000-0001-7031-6498","observed_orcids":["https://orcid.org/0000-0001-7031-6498"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ran Abuhasira","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087655468","display_name":"Hyon K. Choi","orcid":"https://orcid.org/0000-0002-2862-0442","observed_orcids":["https://orcid.org/0000-0002-2862-0442"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hyon K Choi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050486419","display_name":"Natalie McCormick","orcid":"https://orcid.org/0000-0002-4147-8348","observed_orcids":["https://orcid.org/0000-0002-4147-8348"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Natalie McCormick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5085621280","display_name":"Nitzan Burrack","orcid":"https://orcid.org/0000-0001-6926-8505","observed_orcids":["https://orcid.org/0000-0001-6926-8505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nitzan Burrack","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10496","display_name":"Pharmaceutical Practices and Patient Outcomes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2717","display_name":"Geriatrics and Gerontology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gout","display_name":"gout","score":0.9350000023841858},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9769999980926514},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9729999899864197},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9660000205039978},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9950000047683716},{"id":"https://openalex.org/keywords/allopurinol","display_name":"allopurinol","score":0.9089999794960022},{"id":"https://openalex.org/keywords/polypharmacy","display_name":"polypharmacy","score":0.7480000257492065},{"id":"https://openalex.org/keywords/serum-uric-acid","display_name":"serum uric acid","score":0.7450000047683716},{"id":"https://openalex.org/keywords/diuretics","display_name":"diuretics","score":0.8539999723434448},{"id":"https://openalex.org/keywords/glucocorticoids","display_name":"glucocorticoids","score":0.8880000114440918},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.9929999709129333},{"id":"https://openalex.org/keywords/colchicine","display_name":"colchicine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/gout-flares","display_name":"gout flares","score":0.6489999890327454},{"id":"https://openalex.org/keywords/target-trial-emulation","display_name":"target trial emulation","score":0.5870000123977661}],"concepts":[{"id":"https://openalex.org/C2780402116","wikidata":"https://www.wikidata.org/wiki/Q133087","display_name":"Gout","level":2,"score":0.909600019454956},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8833000063896179},{"id":"https://openalex.org/C2780261098","wikidata":"https://www.wikidata.org/wiki/Q412486","display_name":"Allopurinol","level":2,"score":0.741100013256073},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6625000238418579},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6431000232696533},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5530999898910522},{"id":"https://openalex.org/C2779721657","wikidata":"https://www.wikidata.org/wiki/Q49970","display_name":"Hyperuricemia","level":3,"score":0.5425999760627747},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5421000123023987},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.42239999771118164},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.3488999903202057},{"id":"https://openalex.org/C50440223","wikidata":"https://www.wikidata.org/wiki/Q1475848","display_name":"Risk factor","level":2,"score":0.34049999713897705},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3352999985218048},{"id":"https://openalex.org/C2779881121","wikidata":"https://www.wikidata.org/wiki/Q105522","display_name":"Uric acid","level":2,"score":0.3264000117778778},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3237999975681305},{"id":"https://openalex.org/C2779668873","wikidata":"https://www.wikidata.org/wiki/Q6693756","display_name":"Lower risk","level":3,"score":0.3197000026702881},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.31619998812675476},{"id":"https://openalex.org/C167704817","wikidata":"https://www.wikidata.org/wiki/Q7295548","display_name":"Rate ratio","level":3,"score":0.31060001254081726},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.29170000553131104},{"id":"https://openalex.org/C2777628954","wikidata":"https://www.wikidata.org/wiki/Q18216","display_name":"Aspirin","level":2,"score":0.28630000352859497},{"id":"https://openalex.org/C2779918671","wikidata":"https://www.wikidata.org/wiki/Q200656","display_name":"Diuretic","level":2,"score":0.28540000319480896},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.26669999957084656},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.26440000534057617},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.2554999887943268},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.2538999915122986}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/figshare.30916430","doi":"https://doi.org/10.2337/figshare.30916430","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.30916430","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.2337/figshare.30916430","doi":"https://doi.org/10.2337/figshare.30916430","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.30916430","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4394812117","https://openalex.org/W4411415137","https://openalex.org/W3213904373","https://openalex.org/W3153310196","https://openalex.org/W4385190651","https://openalex.org/W4294415605","https://openalex.org/W2999396735","https://openalex.org/W4399481326","https://openalex.org/W4294782897","https://openalex.org/W7122673401"],"abstract_inverted_index":{"Objectives:":[0],"Sodium-glucose":[1],"cotransporter-2":[2],"inhibitors":[3,51],"(SGLT2i)":[4],"lower":[5,12,141,188],"serum":[6,39,118,175],"urate":[7,119,176],"and":[8,28,36,67,79,84,89,120,128,165,172,177,195,211,221,244],"are":[9],"associated":[10,186],"with":[11,44,55,77,92,114,126,147,187,198,219],"risk":[13],"of":[14,25,30,95,190,201,242],"recurrent":[15],"gout":[16,45,78,127,220],"flares.":[17],"We":[18,105],"used":[19,85],"target-trial":[20],"emulation":[21],"to":[22,98,101,170,237],"compare":[23],"rates":[24,189],"allopurinol":[26],"initiation":[27,139],"use":[29],"anti-inflammatories":[31],"(high-dose":[32],"glucocorticoids,":[33],"NSAIDs,":[34],"colchicine)":[35],"diuretics":[37,161],"(prototypic":[38],"urate-raising":[40],"medication)":[41],"among":[42,142,158],"patients":[43,76,218],"using":[46,160],"SGLT2i":[47,102,143,169,183,225],"versus":[48],"dipeptidyl":[49],"peptidase-4":[50],"(DPP-4i;":[52],"primary":[53],"comparator),":[54],"glucagon-like":[56],"peptide-1":[57],"receptor":[58],"agonists":[59],"(GLP1-RA)":[60],"as":[61],"an":[62,111],"alternative":[63],"comparator.":[64],"Research":[65],"Design":[66],"Methods:":[68],"From":[69],"a":[70],"general":[71],"population":[72],"database,":[73],"we":[74],"identified":[75],"comorbid":[80],"type":[81,129,222],"2":[82,130,223],"diabetes":[83,131],"Cox":[86],"proportional":[87],"hazards":[88],"Poisson":[90],"regressions":[91],"inverse":[93],"probability":[94],"treatment":[96],"weighting":[97],"emulate":[99],"randomisation":[100],"or":[103],"DPP-4i/GLP1-RA.":[104],"also":[106,185],"replicated":[107],"the":[108,180,238],"analysis":[109],"in":[110,179,233,246],"EHR":[112],"dataset":[113],"further":[115],"adjustment":[116],"for":[117,174],"BMI.":[121],"Results:":[122],"Among":[123],"26,739":[124],"adults":[125],"(mean":[132],"age":[133],"66),":[134],"67%":[135],"had":[136],"polypharmacy.":[137],"Allopurinol":[138],"was":[140,184],"initiators":[144],"than":[145],"DPP-4i,":[146],"hazard":[148],"ratio":[149],"0.62":[150],"(95%":[151],"CI:":[152],"0.52,":[153],"0.73).":[154],"Associations":[155],"were":[156],"stronger":[157],"those":[159],"at":[162],"baseline":[163],"(p-interaction=0.03)":[164],"persisted":[166],"when":[167],"comparing":[168],"GLP1-RA,":[171],"accounting":[173],"BMI":[178],"secondary":[181],"dataset.":[182],"high-dose":[191],"glucocorticoid,":[192],"NSAID,":[193],"colchicine,":[194],"diuretic":[196],"dispensing,":[197],"rate":[199],"ratios":[200],"0.78":[202],"(0.74,":[203],"0.83),":[204],"0.85":[205],"(0.80,":[206],"0.92),":[207,210],"0.87":[208,212],"(0.83,":[209],"(0.85,":[213],"0.89),":[214],"respectively.":[215],"Conclusions:":[216],"For":[217],"diabetes,":[224],"may":[226],"reduce":[227,235],"gout-related":[228],"medication":[229],"use,":[230],"which":[231],"could,":[232],"turn,":[234],"exposure":[236],"harmful":[239],"cardiovascular-kidney-metabolic":[240],"effects":[241],"NSAIDs":[243],"glucocorticoids":[245],"this":[247],"high-risk":[248],"population.":[249]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2026-02-01T00:00:00"}